Rhumbline Advisers Acquires 2,466 Shares of Enliven Therapeutics, Inc. $ELVN

Rhumbline Advisers boosted its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 4.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,502 shares of the company’s stock after purchasing an additional 2,466 shares during the quarter. Rhumbline Advisers owned about 0.11% of Enliven Therapeutics worth $1,033,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth $789,000. Millennium Management LLC grew its position in shares of Enliven Therapeutics by 108.6% in the 4th quarter. Millennium Management LLC now owns 50,804 shares of the company’s stock valued at $1,143,000 after buying an additional 26,449 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Enliven Therapeutics by 67.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock valued at $984,000 after buying an additional 17,546 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics in the 4th quarter valued at about $112,000. Finally, Deutsche Bank AG boosted its position in shares of Enliven Therapeutics by 51.7% during the 4th quarter. Deutsche Bank AG now owns 30,516 shares of the company’s stock valued at $687,000 after purchasing an additional 10,397 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Down 4.8%

Shares of ELVN opened at $18.96 on Friday. The business’s fifty day simple moving average is $20.11 and its two-hundred day simple moving average is $19.66. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -9.48 and a beta of 0.89. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $20.24, for a total transaction of $134,940.08. Following the completion of the transaction, the chief operating officer owned 283,308 shares in the company, valued at $5,734,153.92. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Samuel Kintz sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $19.09, for a total value of $95,450.00. Following the transaction, the chief executive officer owned 922,892 shares of the company’s stock, valued at $17,618,008.28. This trade represents a 0.54% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,234 shares of company stock valued at $1,756,514. 25.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have issued reports on ELVN shares. Robert W. Baird increased their price target on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, June 16th. HC Wainwright increased their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, July 2nd. Finally, The Goldman Sachs Group started coverage on Enliven Therapeutics in a report on Monday, June 16th. They issued a “buy” rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.